Document text
Principal Investigator: Ian David Aronson
Organization: NDRI-USA, INC.
Fiscal Year: 2024
Award: $461,653
Funding agency: National Institute on Drug Abuse
Project Summary/Abstract
People who inject drugs (PWID) experience disproportionate risk of being infected with SARS-CoV-2,
the virus that causes COVID-19. Unfortunately, due to stigma, fear of mistreatment, and other factors, PWID are
far less likely to be vaccinated compared to other populations. African American and Latino populations also
face disproportionate risk of infection and far greater COVID-19 death rates compared to White populations, yet
due to issues including longstanding medical mistrust are also far less likely to vaccinate. For African American
and Latino PWID, COVID-related risks increase even further and vaccination becomes even more unlikely.
In response, we propose to continue our collaboration with New York Harm Reduction Educators
(NYHRE) a prominent New York City community based organization serving African American and Latino PWID.
To increase SARS-CoV-2 vaccination among our target population, we will first assemble a community advisory
board (CAB) that we will consult at all phases of the project, then conduct a series of qualitative interviews (n=20)
to better understand barriers to testing and vaccination among PWID, and how we can potentially address these
via technology-based messaging. We will then work with our CAB and additional PWID participants (n=30) to
iteratively develop, evaluate, and refine intervention video and text message content in English and Spanish.
Next, we will recruit a separate sample of PWID (n=500) via respondent driven sampling to evaluate
these newly created intervention materials as part of a clinical trial. Upon enrollment, participants will be offered
a free vaccination against SARS-CoV-2. To increase the rigor of our trial, we will only provide our intervention
materials to participants who do not accept vaccination when offered (based on current rates of PWID vaccination
against influenza we expect the overwhelming majority will decline). Those who do not initially vaccinate will be
randomized into one of two intervention groups: a no video group, and a video text group. The no video group
will receive weekly text messages designed to address barriers to vaccination identified in formative research.
The video text group will receive the same texts, along with links to videos we develop with NYHRE staff and
clients to address barriers to SARS-CoV-2 vaccination. Our intervention will track response rates in both groups.
Primary outcome measures will be vaccination within the initial weeks following enrollment and the subsequent
intervention period by treatment group. Additional outcomes will include vaccination rates by demographic,
including race/ethnicity and primary language (i.e. do English speaking participants respond differently to specific
intervention components compared to monolingual Spanish speakers).
If shown successful this approach can be replicated with additional populations that experience health
disparities, and in different languages across the United States.
Terms: <2019 novel corona virus><2019 novel coronavirus><2019-nCoV><2019-nCoV vaccine><AIDS Virus><Acquired Immune Deficiency Syndrome Virus><Acquired Immunodeficiency Syndrome Virus><Active Follow-up><Address><African American><Afro American><Afroamerican><Age><Area><COVID complications><COVID related complications><COVID-19><COVID-19 affected><COVID-19 associated death><COVID-19 associated fatality><COVID-19 associated mortality><COVID-19 complications><COVID-19 consequence><COVID-19 death><COVID-19 effect><COVID-19 fatality><COVID-19 impact><COVID-19 impacted><COVID-19 induced death><COVID-19 induced fatality><COVID-19 induced mortality><COVID-19 infection><COVID-19 mortality><COVID-19 related complications><COVID-19 related death><COVID-19 related fatality><COVID-19 related mortality><COVID-19 related risk><COVID-19 risk><COVID-19 risk factor><COVID-19 vaccination><COVID-19 vaccine><COVID-19 virus><COVID-19 virus infection><COVID19 associated death><COVID19 associated fatality><COVID19 associated mortality><COVID19 death><COVID19 fatality><COVID19 induced death><COVID19 induced fatality><COVID19 induced mortality><COVID19 infection><COVID19 mortality><COVID19 related death><COVID19 related fatality><COVID19 related mortality><COVID19 virus><CV-19><Cell Phone><Cellular Phone><Cellular Telephone><Charge><Client><Clinical Trials><CoV-2><CoV2><Collaborations><Communities><Consult><Coronavirus Infectious Disease 2019><Criminal Justice><Crowding><Data><Death Rate><Dose><Drops><Drugs><Enrollment><Ensure><Espanol><Ethnic Origin><Ethnicity><Face><Fear><Feedback><Flu vaccination><Fright><Gender><HBV Vaccination><HCV/HIV><HIV><HIV and HCV><HIV and hepatitis C><HIV-HCV><HIV/HCV><HIV/Hepatitis C><Handwashing><Harm Minimization><Harm Reduction><Hep B vaccination><Hepatitis A><Hepatitis B Vaccination><Hepatitis B immunization><Hepatitis B injection><Hepatitis B series immunization><Homelessness><Human Immunodeficiency Viruses><Hydrogen Oxide><Individual><Influenza immunization><Influenza vaccination><Injecting drug user><Injection Drug User><Intervention><Intervention Strategies><Interview><LAV-HTLV-III><Language><Latino><Latino Population><Latino group><Latino individual><Latino people><Latinos><Link><Location><Lymphadenopathy-Associated Virus><M tuberculosis infection><M. tb infection><M. tuberculosis infection><M.tb infection><M.tuberculosis infection><MTB infection><Medical><Medication><Methods><Mobile Phones><Mycobacterium tuberculosis (MTB) infection><Mycobacterium tuberculosis infection><New York><New York City><Outcome><Outcome Measure><PWID><Participant><Persons><Pharmaceutical Preparations><Phase><Physical distancing><Population><Population Intervention><Prophylactic vaccination against influenza><Race><Races><Randomized><Research><Respondent><Risk><SARS corona virus 2><SARS-CO-V2><SARS-COVID-2><SARS-CoV-2><SARS-CoV-2 associated death><SARS-CoV-2 associated fatality><SARS-CoV-2 associated mortality><SARS-CoV-2 death><SARS-CoV-2 fatality><SARS-CoV-2 induced death><SARS-CoV-2 induced fatality><SARS-CoV-2 induced mortality><SARS-CoV-2 infection><SARS-CoV-2 mortality><SARS-CoV-2 related death><SARS-CoV-2 related fatality><SARS-CoV-2 related mortality><SARS-CoV-2 vaccination><SARS-CoV-2 vaccine><SARS-CoV2><SARS-CoV2 infection><SARS-associated corona virus 2><SARS-associated coronavirus 2><SARS-coronavirus-2><SARS-coronavirus-2 vaccine><SARS-related corona virus 2><SARS-related coronavirus 2><SARSCoV2><Sampling><Series><Severe Acute Respiratory Coronavirus 2><Severe Acute Respiratory Distress Syndrome CoV 2><Severe Acute Respiratory Distress Syndrome Corona Virus 2><Severe Acute Respiratory Distress Syndrome Coronavirus 2><Severe Acute Respiratory Syndrome CoV 2><Severe Acute Respiratory Syndrome CoV 2 vaccine><Severe Acute Respiratory Syndrome-associated coronavirus 2><Severe Acute Respiratory Syndrome-related coronavirus 2><Severe acute respiratory syndrome associated corona virus 2><Severe acute respiratory syndrome coronavirus 2><Severe acute respiratory syndrome coronavirus 2 infection><Severe acute respiratory syndrome coronavirus 2 vaccination><Severe acute respiratory syndrome coronavirus 2 vaccine><Severe acute respiratory syndrome related corona virus 2><Shelter facility><Site><Social Distance><Spanish><Spanish/English><Structure><Substance Use Disorder><TB infection><Tablet Computer><Tablets><Target Populations><Technology><Testing><Text><Text Messaging><Treatment Period><Trust><Tuberculosis><United States><Vaccinated><Vaccination><Vaccines><Virus><Virus-HIV><Water><Work><Wuhan coronavirus><accept vaccination><accept vaccine><access to health care><access to healthcare><access to vaccination><access to vaccines><accessibility of health care><accessibility to health care><accessibility to healthcare><active followup><ages><automated text message><automated texting><barrier to testing><community advisory board><community advisory committee><community advisory panel><community based organizations><community organizations><complications due to COVID-19><consults><coronavirus disease 2019><coronavirus disease 2019 associated death><coronavirus disease 2019 associated fatality><coronavirus disease 2019 associated mortality><coronavirus disease 2019 consequence><coronavirus disease 2019 death><coronavirus disease 2019 effect><coronavirus disease 2019 fatality><coronavirus disease 2019 impact><coronavirus disease 2019 induced death><coronavirus disease 2019 induced fatality><coronavirus disease 2019 induced mortality><coronavirus disease 2019 infection><coronavirus disease 2019 mortality><coronavirus disease 2019 related death><coronavirus disease 2019 related fatality><coronavirus disease 2019 related mortality><coronavirus disease 2019 risk><coronavirus disease 2019 risk factor><coronavirus disease 2019 vaccination><coronavirus disease 2019 vaccine><coronavirus disease 2019 virus><coronavirus disease-19><coronavirus disease-19 impact><coronavirus disease-19 mortality><coronavirus disease-19 vaccine><coronavirus disease-19 virus><coronavirus infectious disease-19><cost><death due to COVID-19><death due to COVID19><death due to SARS-CoV-2><death due to coronavirus disease 2019><death due to severe acute respiratory syndrome coronavirus 2><death in COVID><death in COVID-19><death in SARS-CoV-2><death in coronavirus disease><death in coronavirus disease 2019><death in severe acute respiratory syndrome coronavirus 2><design><designing><disparity in health><disseminated TB><disseminated tuberculosis><drug/agent><enroll><ethnic minority><experience><faces><facial><fatality due to COVID-19><fatality due to COVID19><fatality due to SARS-CoV-2><fatality due to coronavirus disease 2019><fatality due to severe acute respiratory syndrome coronavirus 2><flu immunisation><follow up><follow-up><followed up><followup><group intervention><hCoV19><hand washing><health care access><health care availability><health care service access><health care service availability><health disparity><health disparity community><health disparity group><health disparity populations><healthcare access><healthcare accessibility><healthcare availability><healthcare service access><healthcare service availability><hepatitis B virus vaccination><hesitant to vaccination><homeless><hurdle to testing><iPhone><immunization against hepatitis B><improved><infected with COVID-19><infected with COVID19><infected with SARS-CoV-2><infected with SARS-CoV2><infected with coronavirus disease 2019><infected with severe acute respiratory syndrome coronavirus 2><infection due to Mycobacterium tuberculosis><infection risk><influenza virus vaccination><intervention refinement><interventional strategy><maltreatment><measurable outcome><mistreatment><mortality due to COVID-19><mortality due to COVID19><mortality due to SARS-CoV-2><mortality due to coronavirus disease 2019><mortality due to severe acute respiratory syndrome coronavirus 2><mortality rate><mortality ratio><nCoV vaccine><nCoV-19 vaccine><nCoV19 vaccine><nCoV2><non vaccinated><not vaccinated><obstacle to testing><outcome measurement><overdose prevention><peer><people who inject drugs><people who inject illicit drugs><persons who inject drugs><population based intervention><population specific intervention><primary outcome><racial><racial background><racial minority group><racial minority individual><racial minority people><racial minority population><racial origin><randomisation><randomization><randomized, clinical trials><randomly assigned><recruit><response><risk associated with COVID-19><risk factor associated with COVID-19><risk factor related to COVID-19><risk related to COVID-19><secondary outcome><severe acute respiratory syndrome coronavirus 2 associated death><severe acute respiratory syndrome coronavirus 2 associated fatality><severe acute respiratory syndrome coronavirus 2 associated mortality><severe acute respiratory syndrome coronavirus 2 death><severe acute respiratory syndrome coronavirus 2 fatality><severe acute respiratory syndrome coronavirus 2 induced death><severe acute respiratory syndrome coronavirus 2 induced fatality><severe acute respiratory syndrome coronavirus 2 induced mortality><severe acute respiratory syndrome coronavirus 2 mortality><severe acute respiratory syndrome coronavirus 2 related death><severe acute respiratory syndrome coronavirus 2 related fatality><severe acute respiratory syndrome coronavirus 2 related mortality><shelter><shelter housing><shelters><short message service><smart phone><smartphone><social stigma><stigma><substance use><substance use and disorder><substance using><tablet device><testing barrier><testing hurdle><testing obstacle><texting><treatment days><treatment duration><treatment group><tuberculosis infection><tuberculous spondyloarthropathy><unhoused><unvaccinated><uptake><vaccinate against COVID-19><vaccinate against SARS-CoV-2><vaccinate against coronavirus disease 2019><vaccinate against severe acute respiratory syndrome coronavirus 2><vaccination acceptability><vaccination acceptance><vaccination access><vaccination against COVID-19><vaccination against SARS-CoV-2><vaccination against Severe acute respiratory syndrome coronavirus 2><vaccination against coronavirus disease 2019><vaccination against hepatitis B><vaccination against influenza><vaccination availability><vaccination confidence><vaccination hesitancy><vaccination uptake><vaccination willingness><vaccine acceptability><vaccine acceptance><vaccine access><vaccine against 2019-nCov><vaccine against COVID-19><vaccine against SARS-CoV-2><vaccine against SARS-coronavirus-2><vaccine against Severe Acute Respiratory Syndrome CoV 2><vaccine against Severe acute respiratory syndrome coronavirus 2><vaccine availability><vaccine candidates against SARS-CoV-2><vaccine confidence><vaccine for novel coronavirus><vaccine hesitancy><vaccine hesitant><vaccine uptake><vaccine willingness><vaccines preventing COVID><vaccines to prevent COVID><ventilation>